Correction to: Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa [0.03%]
关于抗体工程在MOv19单克隆抗体衍生物生成中的作用的更正：针对叶酸受体阿尔法的40年生物/治疗工具发展历程
[This corrects the article DOI: 10.1093/abt/tbac026.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 May 15;7(2):187. DOI:10.1093/abt/tbae010 2024
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy [0.03%]
一个实验验证的抗原特异性癌症治疗的主要组织相容性复合体表位整合数据库
Satoru Kawakita,Aidan Shen,Cheng-Chi Chao et al.
Satoru Kawakita et al.
Cancer immunotherapy represents a paradigm shift in oncology, offering a superior anti-tumor efficacy and the potential for durable remission. The success of personalized vaccines and cell therapies hinges on the identification of immunogen...
A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains [0.03%]
抗体多样性的一种新机制：含有LAIR1和LILRB1胞外区的天然型抗体的产生
Yuanzhi Chen,Zhiren Zeng,Ziyou Chen et al.
Yuanzhi Chen et al.
The recent discovery of public antibodies targeting Plasmodium falciparum-encoded repetitive interspersed families of polypeptides (RIFINs), which contain extracellular immunoglobulin-like domains from LAIR1 or LILRB1, constitutes a signifi...
Correction to: Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate [0.03%]
固态肿瘤治疗改革的纠正：较小格式抗体-药物偶联物的新兴潜力的修正版
[This corrects the article DOI: 10.1093/abt/tbae005.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 Jun 17;7(2):188. DOI:10.1093/abt/tbae015 2024
Structure and function of therapeutic antibodies approved by the US FDA in 2023 [0.03%]
2023年美国FDA批准的治疗性抗体的结构与功能
William R Strohl
William R Strohl
In calendar year 2023, the United States Food and Drug Administration (US FDA) approved a total of 55 new molecular entities, of which 12 were in the class of therapeutic antibodies. Besides antibody protein drugs, the US FDA also approved ...
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate [0.03%]
实体瘤治疗革新：小型抗体药物偶联物的新兴潜力
Xiaojie Ma,Mingkai Wang,Tianlei Ying et al.
Xiaojie Ma et al.
In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires su...
Correction to: Bringing cell therapy to tumors: considerations for optimal CAR binder design [0.03%]
Correction to: 带着细胞疗法去找肿瘤：关于最佳CAR结合子设计的考虑因素
[This corrects the article DOI: 10.1093/abt/tbad019.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 Feb 14;7(2):131. DOI:10.1093/abt/tbae003 2024
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA [0.03%]
采用加速质量谱和酶联免疫吸附法互补研究rhIL-7-hyFC的药代动力学行为
Anhye Kim,Min-Seok Oh,Gwan-Ho Lee et al.
Anhye Kim et al.
Antibody-based therapeutics (ABTs), including monoclonal/polyclonal antibodies and fragment crystallizable region (Fc)-fusion proteins, are increasingly used in disease treatment, driving the global market growth. Understanding the pharmaco...
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential [0.03%]
一种具有抗过敏和抗癌潜力的新型人源化TSLP单克隆抗体HZ-1127的研究开发
Xiaolei Liu,Jianzhong Han,Qian Wang et al.
Xiaolei Liu et al.
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces. Recent studies found dysregulation of the TSLP-TSLP recep...
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy [0.03%]
GB12-09，一种双特异性抗体，针对IL4Rα和IL31Rα用于治疗特应性皮炎
Feiyan Deng,Yuxin Qiu,Xiangling Zhang et al.
Feiyan Deng et al.
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by dysregulated immune responses. The key mediators of AD pathogenesis are T helper 2 (TH2) cells and TH2 cytokines. Targeting interleukin 4 (IL4), IL13 or IL31 h...